We are sometime not sure what to make of pharmacy monographs. You know what we mean. Those sheets that pharmacists print out and give us with our prescriptions. They are not drug labeling, and they are not medication guides. They are summaries intended for patient perusal, with information taken from the labeling, but digested in a fashion intended for the lay reader. Notably, the FDA has not asserted any prerogative to review and approve pharmacy monographs, leaving publishers essentially self-regulated under an FDA action plan.
Hardin, at *6. We use the saying “this argument proves too much” in carefully chosen spots, including this one. This argument proves too much because the subject matter at issue is prescription drug monographs. All drugs present risks to human health, and anyone who prepares or transmits information regarding the use of prescription drugs can foresee a possible impact on patients. As a result, this court’s rationale would produce a duty with no end, which is clearly not the law in California or anywhere else. Nor should it be. Even this court had to concede that no other court in California has ever found such a duty.